Page 980«..1020..979980981982..9901,000..»

From the Archives (June 8, 1970): When man plays god – The Hindu

Posted: June 8, 2020 at 2:53 am

From Mendel who a century ago formulated his famous laws of heredity to Khorana who has just succeeded in producing a synthetic gene, the biochemical unit of inheritance, is a long and exciting story. But the first, major breakthrough was achieved only in the past decade with the discovery and isolation of the mysterious D.N.A. (deoxiribonucleic acid) and R.N.A. (ribonucleic acid), the basic substances in the living cell, respectively carrying the predestined pattern of life (or the genetic code) and the means of its communication to final expression. The remarkable achievement of the team of scientists of the Wisconsin University, headed by Dr. H. G. Khorana, takes these probes into the very nature of life a big step forward. Whether it will also bring within man's grasp, in the foreseeable future, the means of tinkering with the genetic code to alter his very being to desired ends is too soon to say. And yet such possibilities of genetic engineering, thrown open by the virtuoso Khorana performance, can be both exciting and frightening.

Excerpt from:
From the Archives (June 8, 1970): When man plays god - The Hindu

Posted in Genetic Engineering | Comments Off on From the Archives (June 8, 1970): When man plays god – The Hindu

Genetically Modified Mosquitoes Could be Released in Florida and Texas This Summer – The Daily Beast

Posted: June 8, 2020 at 2:53 am

This article originally appeared on The Conversation.

This summer, for the first time, genetically modified mosquitoes could be released in the U.S.

On May 1, 2020, the company Oxitec received an experimental use permit from the U.S. Environmental Protection Agency to release millions of GM mosquitoes (labeled by Oxitec as OX5034) every week over the next two years in Florida and Texas. Females of this mosquito species, Aedes aegypti, transmit dengue, chikungunya, yellow fever and Zika viruses. When these lab-bred GM males are released and mate with wild females, their female offspring die. Continual, large-scale releases of these OX5034 GM males should eventually cause the temporary collapse of a wild population.

However, as vector biologists, geneticists, policy experts and bioethicists, we are concerned that current government oversight and scientific evaluation of GM mosquitoes do not ensure their responsible deployment.

Coral reefs that can withstand rising sea temperatures, American chestnut trees that can survive blight and mosquitoes that cant spread disease are examples of how genetic engineering may transform the natural world.

Genetic engineering offers an unprecedented opportunity for humans to reshape the fundamental structure of the biological world. Yet, as new advances in genetic decoding and gene editing emerge with speed and enthusiasm, the ecological systems they could alter remain enormously complex and understudied.

Recently, no group of organisms has received more attention for genetic modification than mosquitoesto yield inviable offspring or make them unsuitable for disease transmission. These strategies hold considerable potential benefits for the hundreds of millions of people impacted by mosquito-borne diseases each year.

Although the EPA approved the permit for Oxitec, state approval is still required. A previously planned release in the Florida Keys of an earlier version of Oxitecs GM mosquito (OX513) was withdrawn in 2016 after a referendum indicated significant opposition from local residents. Oxitec has field-trialed their GM mosquitoes in Brazil, the Cayman Islands, Malaysia and Panama.

The public forum on Oxitecs recent permit application garnered 31,174 comments opposing release and 56 in support. The EPA considered these during their review process.

However, it is difficult to assess how EPA regulators weighed and considered public comments and how much of the evidence used in final risk determinations was provided solely by the technology developers.

The closed nature of this risk assessment process is concerning to us.

There is a potential bias and conflict of interest when experimental trials and assessments of ecological risk lack political accountability and are performed by, or in close collaboration with, the technology developers.

This scenario becomes more troubling with a for-profit technology company when cost- and risk-benefit analyses comparing GM mosquitoes to other approaches arent being conducted.

Another concern is that risk assessments tend to focus on only a narrow set of biological parameterssuch as the potential for the GM mosquito to transmit disease or the potential of the mosquitoes new proteins to trigger an allergic response in peopleand neglect other important biological, ethical and social considerations.

To address these shortcomings, the Institute for Sustainability, Energy and Environment at University of Illinois Urbana-Champaign convened a Critical Conversation on GM mosquitoes. The discussion involved 35 participants from academic, government and nonprofit organizations from around the world with expertise in mosquito biology, community engagement and risk assessment.

A primary takeaway from this conversation was an urgent need to make regulatory procedures more transparent, comprehensive and protected from biases and conflicts of interest. In short, we believe it is time to reassess risk assessment for GM mosquitoes. Here are some of the key elements we recommend.

First, an official, government-funded registry for GM organisms specifically designed to reproduce in the wild and intended for release in the U.S. would make risk assessments more transparent and accountable. Similar to the U.S. database that lists all human clinical trials, this field trial registry would require all technology developers to disclose intentions to release, information on their GM strategy, scale and location of release and intentions for data collection.

This registry could be presented in a way that protects intellectual property rights, just as therapies entering clinical trials are patent-protected in their registry. The GM organism registry would be updated in real time and made fully available to the public.

Second, a broader set of risks needs to be assessed and an evidence base needs to be generated by third-party researchers. Because each GM mosquito is released into a unique environment, risk assessments and experiments prior to and during trial releases should address local effects on the ecosystem and food webs. They should also probe the disease transmission potential of the mosquitos wild counterparts and ecological competitors, examine evolutionary pressures on disease agents in the mosquito community and track the gene flow between GM and wild mosquitoes.

To identify and assess risks, a commitment of funding is necessary. The U.S. EPAs recent announcement that it would improve general risk assessment analysis for biotechnology products is a good start. But regulatory and funding support for an external advisory committee to review assessments for GM organisms released in the wild is also needed; diverse expertise and local community representation would secure a more fair and comprehensive assessment.

Furthermore, independent researchers and advisers could help guide what data are collected during trials to reduce uncertainty and inform future large-scale releases and risk assessments.

The objective to reduce or even eliminate mosquito-borne disease is laudable. GM mosquitoes could prove to be an important tool in alleviating global health burdens. However, to ensure their success, we believe that regulatory frameworks for open, comprehensive and participatory decision-making are urgently needed.

Written by Brian Allan, Associate Professor of Entomology, University of Illinois at Urbana-Champaign; Chris Stone, Medical Entomologist, University of Illinois at Urbana-Champaign; Holly Tuten, Vector Ecologist, University of Illinois at Urbana-Champaign; Jennifer Kuzma, Goodnight-NCGSK Distinguished Professor, North Carolina State University; Natalie Kofler, Levenick Resident Scholar in Sustainability, University of Illinois at Urbana-Champaign.

Read the rest here:
Genetically Modified Mosquitoes Could be Released in Florida and Texas This Summer - The Daily Beast

Posted in Genetic Engineering | Comments Off on Genetically Modified Mosquitoes Could be Released in Florida and Texas This Summer – The Daily Beast

Scientists have created a new method of treatment of type I diabetes – The Times Hub

Posted: June 8, 2020 at 2:53 am

Scientists Childrens research center of Seattle has created a new method of treatment of type I diabetes. They used certain types of immune cells that trigger insulin production.

Researchers have proposed a technology that provides the organism with the necessary amount of the named substance. Type one diabetes is a disease in which effector T cells mistakenly attack the immune cell structures in the pancreas that produce insulin. The new method relates to genetic engineering and provides for the use of this mechanism. The function of immune cells is to capture the excess level of glucose in the blood, after that they produce insulin. The destruction of the latter they are not able to isolate this hormone, later in the blood glucose levels. Experts have edited the genes to home in on the genetic structure of FOXP3 in T-cells.

Scientists have created a special manual for these items as they play a crucial in the activation of cells of the pancreas, contributing to the production of the required insulin. In further studies, the experts will prepare a platform for clinical trials of a new method of treatment of diabetes of the first type.

Originally posted here:
Scientists have created a new method of treatment of type I diabetes - The Times Hub

Posted in Genetic Engineering | Comments Off on Scientists have created a new method of treatment of type I diabetes – The Times Hub

Global CRISPR-Based Therapeutics Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 – Jewish Life News

Posted: June 8, 2020 at 2:53 am

The market research on Global CRISPR-Based Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025 presents an in-depth analysis of market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data. The report aims to identify the dynamics of the global CRISPR-Based Therapeutics market and provide recent updates and insights that affect various segments of the global market. The market report sorts the market dependent on the manufacturer, region, type, and application. The report estimates and validates the market size of the global CRISPR-Based Therapeutics market. The report also delivers a forecast, which focuses on the market opportunities for the next five years (2020-2025) for each region. The scope of the study segments the global market by product type, application, end-use, and the region is explained. This research report is expected to enable clients to assess strategies deployed by market leaders.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/41907

Company Profiles:

The report provides immense detailing on each and every company. It incorporates their headquarter location, company overview, recent developments, and company strategies. Market share analysis as per different companies, market forecast, demand, price analysis, size, and share as per regional boundaries has been presented in the report. The report gives a study on global CRISPR-Based Therapeutics industry-top players depending on their company profile, product portfolio, ability, cost, and revenue.

Key market players: Caribou Biosciences , Thermo Fisher Scientific , Merck KGaA , Addgene , Takara Bio USA , CRISPR THERAPEUTICS , Intellia Therapeutics , Editas Medicine , Mirus Bio LLC , Horizon Discovery Group , GE Healthcare Dharmacon

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate for each application: Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type: Genome Editing, Genetic Engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-crispr-based-therapeutics-market-41907

Regional Analysis of The Market:

The report represents all the regions as well as countries across the globe, which showcases a regional manufacturing status, such as volume, market size, value, and price details. Regional analysis is given by tracing the historical forecast market size. It provides complete information about the key developed regions as well as major emerging markets depending on the regional growth of the global CRISPR-Based Therapeutics industry. The anticipated development rate to be recorded by every locale over the conjecture years has been expressed in this report. In terms of geography, the report highly focuses on showcase development, development rate, and development potential. The report studies key players and provides a five-year annual trend analysis, which highlights market size, volume, and share for North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East& Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

See more here:
Global CRISPR-Based Therapeutics Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 - Jewish Life News

Posted in Genetic Engineering | Comments Off on Global CRISPR-Based Therapeutics Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 – Jewish Life News

The pandemic, the environment and Cuba – OnCubaNews

Posted: June 8, 2020 at 2:53 am

Help us keep OnCuba alive here

Perhaps it is difficult to find a moment in the history of humanity in which, in such a short time, such an enormous volume of information (and disinformation) has been generated about a problem that affects the entire human species, as what has happened with the COVID-19 pandemic. Nor has humanity faced such an uncertain near future.

In addition to the global health emergency, which has caused hundreds of thousands of deaths and more than 2 million infected people worldwide, this pandemic has put on the political table the unsustainability of the capitalist system worldwide, the paradigm of unlimited growth and the culture of growing consumer.

On Earth Day Coronavirus, a pollution hiccup?

Suddenly, the reality that we live on a limited planet, with increasingly scarce resources, and that in the biosphere all existence is interconnected, has unquestionably emerged. The zoonotic nature of the COVID-19 itself tells us of the direct transmission of the virus to humans, most likely due to the contact or consumption of wild species and even due to the natural boundaries being displaced and the loss of biodiversity. The fact that it expands globally also alerts us to the profound environmental changes caused by human action and its techno-industrial culture developed on the basis of fossil energy. We have to think about what can happen when, as a result of climate change, the thaws continue and the paleo viruses frozen thousands of years ago are released, in a period too fast for existing species, and especially humans, to adapt to that change. If we add to the above the unsustainability of production systems and value chains (think of stabled livestock, large extensions of monocultures, the application to these systems of agrochemicals, hormones, antivirals and genetic manipulation), we will have an approximate picture of the world that will emerge after the pandemic

This will be a challenge not only for science, which will have to rethink a series of paradigms, but also for world politics that has taken too long to have global agreements to slow down or minimize these processes; hence, one of the elements that should emerge from this experience at the global level is a more direct relationship between science and political decision-making at the country level.

After this pandemic, there will be no new normal, another world will have to be built and that construction will be carried out by all, with greater solidarity and conscious citizen participation, or it will be exercised through increasingly more authoritarian mechanisms of power; we can already see these trends in some governments.

The world as we have known it was structured from obtaining cheap fossil energy, which allowed a techno-industrial culture to develop in the last 200 years that led to the emergence of large human concentrations in megacities. The United Nations has predicted that the urban population will increase to 6.7 billion; that is, 68% of humanity by 2050. In that decade, if the current rhythm continues, there will be 43 megacities with more than 10 million inhabitants each, really something unsustainable for the planet. Current and future generations will be forced to rethink their lifestyles or be willing to live in a dystopian world of isolation, in which relationships must be mediated by technology.

The advances in technoscience in the last 20 years already present us with a new ethics, in which each human being is aware of their limits of all kinds.

Genetic engineering, with all its potential, implies the application of the precautionary principle for the introduction of each technological advance. We are still unaware of the many effects of new technologies on our health and the global environment, yet we continue to use them too frequently.

Over the past few months we have often seen on social media claims about the short-term recovery of natural spaces and wildlife activity in urban areas, dolphins swimming placidly in Venices canals, goats visiting Scottish historical sites, wild boars rummaging through the garbage in Paris and Barcelona. We have been glad that our brothers of other species recover their ancestral spaces even when it was our presence that expelled them; but this is all a fallacy. The processes of environmental deterioration at the planetary level continue, and their resilience, if they can start being reversed, will take years, but we have to start. Just think about these figures: in 2018, the burning of fossil fuels pumped 37.1 billion tons of carbon dioxide into the atmosphere. If we add to this the net carbon emissions caused by soil oxidation and the most vigorous forest fires, we can see why atmospheric concentrations of carbon dioxide reached an all-time high of 415 parts per million in early 2019.

Cubas challenges

Cuba has a different but contradictory panorama. A poor country, blocked for 60 years by the worlds greatest power and with a frankly deteriorating open economy (it is estimated that its GDP will decrease between 4 and 7% in 2020), with a large debt, without external financing, with a high rate of illiquidity, with a country risk like never before, perhaps it is the deepest point of the systemic crisis of its economy. This really places it in a very critical situation, above all due to the enormous supply crisis that threatens to become a food crisis as acute as that of the early 1990s. From the economic point of view, the only alternative is unblocking the mechanisms and to rapidly start applying the agreements contained in the Guidelines discussed massively 10 years ago and which inexplicably have not been applied.

I think that all Cubans could agree on the urgency of doing away with obstacles to agricultural production, the inefficiency of this sector and the dreadful methods of administration and management, which contrast with the statistics that show that most of the national food production is generated by small producers, then the assessment still has blank questions. Advancing towards an agriculture with low energy inputs, sustainable management of the soil and crops, rational use of water, that is, organic agriculture will benefit everyone, there are examples and very successful at that.

Cuba has potentialities that must be taken into account from an environmental point of view and that have been gradually implemented. Its energy dependence constitutes an Achilles heel for its economy and attempts are being made, with a very successful intensive policy, to decrease it with an accelerated increase in clean energy; the Cuban aquifer stock is limited, but the country has a very intelligent and well-structured water policy.

The development of the Cuban health policy with the pandemic has been successful so far and there is no indication that wont continue like this; the Cuban experience in the detection and control of epidemics has made it possible to establish mechanisms of local control and primary care that other countries have not been able to implement, just remember that Cuban doctors have participated in the control and treatment of epidemics such as Ebola in Africa and cholera in Haiti, in addition to the epidemics that for decades have been introduced in Cuba by foreign aggressions (swine fever, dengue, etc.). It is possible to think, unlike other countries, that the island will emerge from the pandemic in a relatively short period of time and with minimal impact on its population. For this reason, the greatest complexity will not be precisely the epidemic, but rather the food supply, and in this direction all the nations efforts must be applied; I say the nation, and not only the state. For its part, the government must open the floodgates to diverse productive forces, the effort is everyones.

On June 2, in commemoration of World Environment Day, the director general of the Environment Agency of the Cuban Ministry of Science, Technology and Environment (CITMA) expressed in a television appearance in Holgun a principle that will have to be present in the next designs of Cuban domestic policies, the interconnection of the natural world with society, or what is the same as the eco-social relationship of all the elements that make up and determine our environment. The relationship of science and politics must recognize that the Cuban territory is limited and all relationship we establish on it has a finite character and has a load capacity that cannot be exceeded. The celebration of June 5 this year is curious, because as always, it is a date in which the environmental work carried out for twelve months by each province and municipality is recognized, but now, in 2020 it will have to be done almost virtually due to the epidemic.

Thinking of Pinar del Ro, a province that this year was the best in its environmental work (the parameters established for the evaluation cover all the activities in the province of the different sectors that tend towards environmental sustainability), brings to mind the need to transfer the financing dedicated to the expansion of tourism to the reactivation and development of agriculture. Tourism is recognized in the world as the smokeless industry, but it is still an industry, it requires the import of all kinds of inputs, as well as being an eminently extractive activity. Today Cuba has a capacity per rooms that is far from the market demand for the island, the existing statistics do not exceed more than 30% of linear occupancy in the various destinations of the archipelago. If we add to this the globalized nature of tourism (it arises precisely with the development of capitalism in its last phase) and the physical interconnections that are established with visitors, even immunologically, we approach a portrait of an activity that is very profitable but that creates links of dependency on a specific and very fragile world market.

According to the activitys development plans in the near future, if the developmentalist vision continues to be applied in the tourism sector, Pinar del Ro will have a huge megaproject called Punta Colorada, which will cost billions of dollars and will have an impact, undoubtedly, on the marine-coastal ecosystems of the northwest of the province and in the Guanahacabibes and Viales biosphere reserves.

The COVID-19 epidemic in the world has put the neoliberal capitalist system in check. It will remain to be seen if it is able to resist this onslaught.

For Cuba it means the need and the urgency to consolidate what exists and works well and transform the inefficient, because for Cuba once again the possibility of creating an eco-socialist alternative with citizen participation is opening.

Help us keep OnCuba alive here

Excerpt from:
The pandemic, the environment and Cuba - OnCubaNews

Posted in Genetic Engineering | Comments Off on The pandemic, the environment and Cuba – OnCubaNews

Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -…

Posted: June 8, 2020 at 2:52 am

ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos Inc., pioneers of the Human-on-a-Chip in vitro system, today announced the publication of a new peer-reviewed publication that describes how the companys technology can be used to investigate immune responses following treatment with biological therapeutics for multi-organ systemic diseases, including cancer, infectious diseases and inflammatory disorders. The study was part of a collaboration between Hesperos, Hoffman-La Roche Pharmaceuticals and the University of Central Florida. The manuscript, titled Differential Monocyte Actuation in a Three-Organ Functional Innate Immune System-on-a-Chip, was published today in the prestigious journal Advanced Science. Click here to view a multimedia version of the press release, including media-ready images, downloadable resources, and more.

The immune system plays an important role in coordinating with other organ systems to combat infection, eliminate damaged cells and repair tissue. However, modeling immune response following drug treatment in preclinical studies is challenging due to poor predictability, especially for the innate portion of the system. As the scientific community begins to turn more towards using multi-organ, human-on-a-chip systems as a cost-effective way to increase efficiency and lower toxicity, many of these models lack a systemic immune component.

Hesperos, in collaboration with Hoffmann-La Roche Pharmaceuticals, describe an in vitro, pumpless, three-organ system containing functional human cardiomyocytes, skeletal muscle and hepatocytes in a serum-free medium, along with recirculating human monocyte THP-1 immune cells. Monocytes are a vital immune system cells involved in wound healing, pathogen clearance and activation of the innate immune response, but are also responsible for the cytokine storm found in conditions such as sepsis.

One application where the immune-system-on-a-chip can be immediately useful is for uncovering how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly affects multi-organ systems by activating the cytokine storm from inflammatory macrophages and to support the rapid development of therapeutics. As the global pandemic of COVID-19 continues to grow, this system has the potential to quickly evaluate antiviral and repurposed drugs to help combat this devastating disease, said Michael L. Shuler, Ph.D., Chief Executive Officer of Hesperos.

In the study, the researchers evaluated two different innate immune responses: 1) targeted immune response following tissue-specific damage, which simulates indirect activation of THP-1 cells and, 2) pro-inflammatory immune response following direct activation of immune cells, mimicking acute inflammation and the cytokine storm. Though not reported in this study, Hesperos has also shown that peripheral blood mononuclear cells (PBMCs) and T-cells are sustainable in these multi-organs systems, which would allow some aspects of adaptive immunity to also be modeled.

In the targeted immune response experiments, the cardiotoxic compound amiodarone was used to selectively damage cardiac cells to evaluate how THP-1 immune cells affect the three-organ system. The presence of both amiodarone and THP-1 immune cells led to a more pronounced reduction in cardiac force, conduction velocity and beat frequency compared to amiodarone alone. THP-1 cells were also found to infiltrate the damaged cardiomyocytes and induce significantly increased cytokine IL-6 expression, indicating an M2 macrophage phenotype. No immune-activated damage was reported in the skeletal muscle or liver cells.

The most striking features of our immune-system-on-a-chip is that it emulates different immune reactions for direct tissue-damage and acute inflammation, as well as distinguishes between M1 vs. M2 macrophage phenotypes, said James Hickman, Ph.D., Chief Scientist at Hesperos and Professor at the University of Central Florida.

The study was initially funded by Roche Pharmaceuticals and completed under an NIH grant from National Center for Advancing Translational Sciences (NCATS) Small Business Innovation Research program, which supports studies to advance tissue chip technology toward commercialization.

Tissue chips are a promising technology for accelerating the preclinical timeline and getting treatments to patients more efficiently, said Danilo A. Tagle, Ph.D., associate director for special initiatives at NCATS. Finding improved ways to study immune responses has tremendous implications for drug discovery and the development of more effective personalized medicines in diseases that affect multiple organ systems.

In the pro-inflammatory response experiments, the three-organ system was exposed to lipopolysaccharide (LPS) and interferon gamma (IFN-) to stimulate acute inflammation/cytokine storm and provoke monocyte differentiation and activation. In the absence of THP-1 immune cells, LPS/IFN- treatment had no significant effect on function of the three-organ system. However, with the addition of THP-1 immune cells, LPS/IFN- treatment caused cellular damage to all three-organ components, including THP-1 cell infiltration in liver tissue, and led to significant alterations in cardiac force and beat frequency, as well as skeletal muscle force. Additionally, there was an upregulation of pro-inflammatory cytokines, including TNF-, IL-6 and IL-10, indicating an M1 macrophage phenotype, which is analogous to the cytokine storm found during certain reactions to biologic therapeutics and emulates what occurs during sepsis.

To read the full manuscript, please visit https://doi.org/10.1002/advs.202000323.

About Hesperos

Hesperos, Inc. is a leader in efforts to characterize an individuals biology with Human-on-a-Chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational PKPD modeling of live physiological responses utilizing functional readouts from neurons, cardiac, muscle, barrier tissues and neuromuscular junctions as well as responses from liver, pancreas and barrier tissues. Created from human stem cells, the fully human systems are the first in vitro solutions that accurately utilize these platforms to predict in vivo functions without the use of animal models, as featured in Science. More information is available at https://hesperosinc.com

Hesperos and Human-on-a-Chip are trademarks of Hesperos Inc. All other brands may be trademarks of their respective holders.

Read this article:
Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -...

Posted in Florida Stem Cells | Comments Off on Hesperos demonstrates innovative Human-on-a-Chip approach to modeling innate immune system response following tissue damage and acute inflammation -…

New Genetic Identification of COVID-19 Susceptibility Will Aid Treatment – SciTechDaily

Posted: June 8, 2020 at 2:49 am

The clinical presentation of Covid-19 varies from patient to patient and understanding individual genetic susceptibility to the disease is therefore vital to prognosis, prevention, and the development of new treatments.

For the first time, Italian scientists have been able to identify the genetic and molecular basis of this susceptibility to infection as well as to the possibility of contracting a more severe form of the disease. The research will be presented to the 53rd annual conference of the European Society of Human Genetics, being held entirely on-line due to the Covid-19 pandemic, today [Saturday].

Professor Alessandra Renieri, Director of the Medical Genetics Unit at the University Hospital of Siena, Italy, will describe her teams GEN-COVID project to collect genomic samples from Covid patients across the whole of Italy in order to try to identify the genetic bases of the high level of clinical variability they showed. Using whole exome sequencing (WES)[1] to study the first data from 130 Covid patients from Siena and other Tuscan institutions, they were able to uncover a number of common susceptibility genes that were linked to a favorable or unfavorable outcome of infection. We believe that variations in these genes may determine disease progression, says Prof Renieri. To our knowledge, this is the first report on the results of WES in Covid-19.

Searching for common genes in affected patients against a control group did not give statistically significant results with the exception of a few genes. So the researchers decided to treat each patient as an independent case, following the example of autism spectrum disorder. In this way we were able to identify for each patient an average of three pathogenic (disease-causing) mutations involved in susceptibility to Covid infection, says Prof Renieri. This result was not unexpected, since we already knew from studies of twins that Covid-19 has a strong genetic basis.

Although presentation of Covid is different in each individual, this does not rule out the possibility of the same treatment being effective in many cases. The model we are proposing includes common genes and our results point to some of them. For example, ACE2 remains one of the major targets. All our Covid patients have an intact ACE2 protein, and the biological pathway involving this gene remains a major focus for drug development, says Prof Renieri. ACE2 is an enzyme attached to the outer surface of several organs, including the lungs, that lowers blood pressure. It serves as an entry point for some coronaviruses, including Covid-19.

These results will have significant implications for health and healthcare policy. Understanding the genetic profile of patients may allow the repurposing of existing medicines for specific therapeutic approaches against Covid-19 as well as speeding the development of new antiviral drugs. Being able to identify patients susceptible to severe pneumonia and their responsiveness to specific drugs will allow rapid public health treatment interventions. And future research will be aided, too, by the development of a Covid Biobank accessible to academic and industry partners.

The researchers will now analyze a further 2000 samples from other Italian regions, specifically from 35 Italian Hospitals belonging to the GEN-COVID project.[2]

Our data, although preliminary, are promising, and now we plan to validate them in a wider population, says Prof Renieri. Going beyond our specific results, the outcome of our study underlines the need for a new method to fully assess the basis of one of the more complex genetic traits, with an environmental causation (the virus), but a high rate of heritability. We need to develop new mathematical models using artificial intelligence in order to be able to understand the complexity of this trait, which is derived from a combination of common and rare genetic factors.

We have developed this approach in collaboration with the Siena Artificial Intelligence Lab, and now intend to compare it with classical genome-wide association studies[3] in the context of the Covid-19 Host Genetics Initiative, which brings together the human genetics community to generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes. As a research community, we need to do everything we can to help public health interventions move forward at this time.

Chair of the ESHG conference, Professor Joris Veltman, Dean of the Biosciences Institute at Newcastle University, Newcastle upon Tyne, UK, said: We are very excited to have this work on the genetics of COVID19 susceptibility presented as one of our late-breaking abstract talks at the ESHG. Our Italian colleagues present the first insight into the role of genetic susceptibility influencing the severity of the response to a COVID19 infection. It needs to be expanded to encompass much larger populations, but it is impressive to see the speed at which research on this virus has proceeded in just a few months time.

Read the original here:
New Genetic Identification of COVID-19 Susceptibility Will Aid Treatment - SciTechDaily

Posted in Genetics | Comments Off on New Genetic Identification of COVID-19 Susceptibility Will Aid Treatment – SciTechDaily

Halo Labs Announces Partnership with Zkittlez Providing Award Winning Genetics in Oregon – Yahoo Finance

Posted: June 8, 2020 at 2:49 am

All Figures in USD

Not for Distribution to U.S. Newswire Servicers or For Dissemination in the United States

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that the Company has entered into an exclusive strategic partnership with Terphogz, LLC ("Zkittlez") to develop and commercialize new and unique cannabis genetics in Oregon.

Background & Partnership Highlights

Terphogz, LLC owns a genetic library that is well-known for creating the famous Zkittlez cannabis variety. Zkittlez has a unique and distinct terpene profile unlike other genetics in the market, making it distinguishable from other strains. Halo has secured a 5-year exclusive partnership with Zkittlez in Oregon to cultivate the groups strains and provide this beloved brand to the Oregon marketplace and consumers for the first time.

Halo will license and have exclusive rights to a large repertoire of genetic strains, most notably Zkittlez, Zmoothi and Z3 Kush. Focusing on the whole plant, Zkittlez has proven that THC alone cant compete with robust and unique terpene profiles. Highly awarded and recognized, the strains will allow Halo develop more brand and retail focused products aligning with the Companys long term growth strategy. With over 200,000 followers on social media and a history of excellence in cannabis genetics, Zkittlez provides extensive value to Halos already strong portfolio of cannabis consumer-centric partnerships.

"We are extremely excited to join forces with Halo. With our award-winning genetics and Halo's cultivation firepower, our collaboration will be a force to be reckoned with in Oregon. Stay tuned, we can't wait to get to work!" comments Green R. Fieldz, CEO of Terphogz, LLC.

Kiran Sidhu CEO and Co-Founder of Halo commented, "We are pleased to be partnering with Terphogz, LLC in Oregon to build a new branded product line of flower, pre-rolls and concentrates. Aligning with a beloved and Emerald Cup award winning brand such as Zkittlez to cultivate existing and develop new cannabis strains demonstrates Halos commitment to offering cannabis consumers access to some of the best genetics. We expect to do more projects with the Terphogz, LLC team and expand the partnership into additional markets."

About Halo

Halo is a leading cannabis cultivation, manufacturing, and distribution company that grows and extracts and processes quality cannabis flower, oils, and concentrates and has sold over 5 million grams of oils and concentrates since inception. Additionally, Halo has continued to evolve its business through delivering value with its products and now via verticalization in key markets in the United States and Africa with planned expansion into European and Canadian markets. With a consumer-centric focus, Halo markets innovative, branded, and private label products across multiple product categories.

Recently, the Company entered into binding agreements to acquire a dispensary in Los Angeles, 3 KushBar branded dispensaries, 5 development permits in Alberta Canada, and Canmart Limited which holds wholesale distribution and special licenses allowing the import and distribution of cannabis based products for medicinal use (CBPMs) in the United Kingdom. Halo is led by a strong, diverse management team with deep industry knowledge and blue-chip experience. The Company is currently operating in the United States in California, Oregon, and Nevada while having an international presence in Lesotho within a planned 200-hectare cultivation zone via Bophelo Bioscience & Wellness (Pty) Ltd. as well as planned importation and distribution in the United Kingdom via Canmart.

For further information regarding Halo, see Halos disclosure documents on SEDAR at http://www.sedar.com.

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Halos beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Halos control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to, statements in respect of the Companys license arrangement with Terphogz, LLC and the cultivation, sale and distribution of Zkittlez branded and other products by the Company.

Story continues

By identifying such information and statements in this manner, Halo is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Halo has made certain assumptions. Although Halo believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Among others, the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: unexpected costs or delays in the completion of the Company's proposed dispensaries and other operation; negative results experienced by the Company as a result of general economic conditions or the ongoing COVID-19 pandemic; delays in the ability of the Company to obtain certain regulatory approvals; unforeseen delays or costs in the completion of the Company's construction projects; adverse changes to demand for cannabis products; ongoing projects by competitors that may impact the relative size of the Companys growing operation; adverse changes in applicable laws; adverse changes in the application or enforcement of current laws, including those related to taxation; increasing costs of compliance with extensive government regulation; changes in general economic, business and political conditions, including changes in the financial markets; risks related to licensing, including the ability to obtain the requisite licenses or renew existing licenses for the Company's proposed operations; dependence upon third party service providers, skilled labor and other key inputs; and the other risks disclosed in the Company's annual information form dated April 16, 2020 and available on the Companys profile at http://www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Halo does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Halo or persons acting on its behalf is expressly qualified in its entirety by this notice.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005962/en/

Contacts

Halo LabsInvestor Relationsinfo@halocanna.com

Read more from the original source:
Halo Labs Announces Partnership with Zkittlez Providing Award Winning Genetics in Oregon - Yahoo Finance

Posted in Genetics | Comments Off on Halo Labs Announces Partnership with Zkittlez Providing Award Winning Genetics in Oregon – Yahoo Finance

Sensitivity is partly in our genes: New study with twins – The New Daily

Posted: June 8, 2020 at 2:49 am

When people respond negatively to an event, even one seemingly benign to others, they might talk of being triggered meaning an emotional button has been pushed, and a discomforting, upsetting or even traumatic experience has been conjured from the past.

Triggering is a big conversation.

The point here is that your reaction to the event is all to do with how the world has treated you.

Less discussed is the fact that some people are more sensitive than others.

Unhappy or stressful moments are felt more deeply: Its just the way they are.

Parents worry about this, sometimes hysterically. One of the kids cries or sooks more easily, more often.

Some wonder: Who did this to our child?

Others quietly lament that theyve spawned a weakling: Some quirk in the genetic marriage. Theyre half right.

A new study from Queen Mary University of London says: Some people are more sensitive to others and around half of these differences can be attributed to our genes.

The researchers, developmental psychologists, compared pairs of identical and non-identical 17-year-old twins to see how strongly they were affected by positive or negative experiences.

The idea was to establish each participants sensitivity level.

The plan was to tease out how much of the differences in sensitivity could be explained by either genetic or environmental factors during development.

As the researchers explain it:

This analysis concluded that 47 per cent of the differences in sensitivity between individuals were down to genetics, leaving 53 per cent accounted for by environmental factors.

The researchers says their study is the first to show this link conclusively in such a large study.

Michael Pluess, Professor of Developmental Psychology at Queen Mary University of London and study lead, said: We are all affected by what we experience sensitivity is something we all share as a basic human trait. But we also differ in how much of an impact our experiences have on us.

Scientists have always thought there was a genetic basis for sensitivity, but this is the first time weve been able to actually quantify how much of these differences in sensitivity are explained by genetic factors.

More than 2800 twins were involved in the study, split between about 1000 identical twins and 1800 non-identical twins, roughly half of whom were same sex.

The twins were asked to fill out a questionnaire, developed by Professor Pluess, which has been widely used to test an individuals levels of sensitivity to their environment.

This test will be made available online later this month so anyone can assess their sensitivity.

The questionnaire is designed to tease out different types of sensitivity whether someone is more sensitive to negative experiences or positive experiences as well as general sensitivity.

Co-researcher Dr Elham Assary said: If a child is more sensitive to negative experiences, it may be that they become more easily stressed and anxious in challenging situations.

On the other hand, if a child has a higher sensitivity to positive experiences, it may be that they are more responsive to good parenting or benefit more from psychological interventions at school.

What our study shows is that these different aspects of sensitivity all have a genetic basis.

The researchers also explored if there was a shared genetic component between sensitivity and the personality traits known as the Big Five.

These are openness, conscientiousness, agreeableness, extraversion and neuroticism.

They found that there was a shared genetic component between sensitivity, neuroticism and extraversion, but not with any of the other personality traits.

Professor Pluess said the findings could help us in how we understand and handle sensitivity, in ourselves and others.

He said: We know from previous research that around a third of people are at the higher end of the sensitivity spectrum. They are generally more strongly affected by their experiences.

This can have both advantages and disadvantages.

Because we now know that this sensitivity is as much due to biology as environment, it is important for people to accept their sensitivity as an important part of who they are and consider it as a strength, not just as a weakness.

Read the original:
Sensitivity is partly in our genes: New study with twins - The New Daily

Posted in Genetics | Comments Off on Sensitivity is partly in our genes: New study with twins – The New Daily

Animal Genetics Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 – Cole of Duty

Posted: June 8, 2020 at 2:49 am

A new market report by Verified Market Research on the Animal Genetics Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Animal Genetics sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=23757&utm_source=COD&utm_medium=007

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Animal Genetics manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Animal Genetics Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=23757&utm_source=COD&utm_medium=007

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Animal Genetics. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Verified Market Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Animal-Genetics-Market/?utm_source=COD&utm_medium=007

Customization of the Report:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Animal Genetics market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Go here to see the original:
Animal Genetics Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 - Cole of Duty

Posted in Genetics | Comments Off on Animal Genetics Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 – Cole of Duty

Page 980«..1020..979980981982..9901,000..»